[Mirabegron, a breakthrough in overactive bladder syndrome?].

Overactive bladder syndrome is a condition with high prevalence, which has a negative impact on patients' quality of life. A drug with a novel mechanism of action has been recently approved: mirabegron. The objective of this study is to review the scientific evidence available on mirabegron, with the aim to analyze its efficacy, safety and cost, and thus estimate its role within current pharmacotherapy.

[Dapagliflozin, a novel oral antidiabetic with an uncertain future].

Objective: Diabetes mellitus type 2 (DM2) is one of the main sociosanitary problems; there are many treatments for it. Recently, it has been approved the first drug of a new family of oral hypoglycemic agents (OHA): dapagliflozin. We aimed to review the available scientific evidence on dapagliflozin, in order to analyze its effectiveness, safety and cost and to estimate its role in the current pharmacotherapy of DM2.

[Plan for improving pharmacy indicators in a primary health area of Madrid. Description and results].

Objective: To evaluate the results of a plan for improving pharmacy indicators in a Primary Care (PC) Health Area.

Design: Quasi-experimental study with a control group. The differences between the pre-intervention (Jan-Dec 2007) and post-intervention (Jan-Dec 2008) periods were evaluated.